Anti-Mouse CD5 (Lyt-1) – Purified

Anti-Mouse CD5 (Lyt-1) – Purified

Product No.: C3122

- -
- -
Clone
53-7.3
Target
CD5 (Lyt-1)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
LY-1, T1, Tp67
Isotype
Rat IgG2a κ
Applications
FC
,
IHC
,
IP

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
Mouse thymus or spleen
Product Concentration
0.5 mg/ml
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
IHC,
IP,
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
53-7.3 activity is directed against mouse CD5 (Lyt-1).
Antigen Distribution
CD5 (Lyt-1) is a marker used to identify T cells, B1-a cells, B cell chronic lymphocytic leukemia cells, regulatory T cell (Tregs), regulatory B cells (IL-10 producing Bregs), and the earliest thymic progenitors. CD5 is also expressed on all lymphocytes except natural killer cells.
Background
CD5 (Lyt-1) is fundamental to immune homeostasis and immune tolerance, with many functions in T and B cells1. CD5 acts as a modulator of T and B cell receptor signaling as well as a cell survival receptor in T and B cells. CD5 is also involved in thymocyte selection, T cell effector differentiation, induces regulatory T cells in the periphery, and modulates Th17 and Th2 differentiation as well as dendritic cell function. Because of its role as an immune checkpoint modulator, CD5 is a target of immunotherapy in the treatment of cancer, autoimmune disease, and infection.

53-7.3 was generated by immunizing LOU/Ws1/M rats with mouse (SJL/J or C3H/HeJ) spleen cells or thymocyte membranes2. Spleen cells were subsequently fused with mouse myeloma NS-1 to produce a hybridoma. The antigen target CD5 (Lyt-1) was confirmed by comparative immunoprecipitation as well as blocking experiments using conventional alloantisera.

Antigen Details

Ligand/Receptor
CD72, gp35-37
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Immunology

References & Citations

1. Burgueño-Bucio E, Mier-Aguilar CA, Soldevila G. J Leukoc Biol. 105(5):891-904. 2019.
2. Ledbetter JA, Rouse RV, Micklem HS, et al. J Exp Med. 152(2):280-295. 1980.
3. Lanier LL, Warner NL, Ledbetter JA, et al. J Exp Med. 153(4):998-1003. 1981.
4. Ledbetter JA, Evans RL, Lipinski M, et al. J Exp Med. 153(2):310-323. 1981.
5. Hollander N. J Immunol. 133(5):2801-2805. 1984.
6. Hollander N, Pillemer E, Weissman IL. Proc Natl Acad Sci U S A. 78(2):1148-1151. 1981.
7. Stanton T, Stevens TL, Ledbetter JA, et al. J Immunol. 136(5):1734-1737. 1986.
8. Capasso M, Bhamrah MK, Henley T, et al. Nat Immunol. 11(3):265-272. 2010.
9. Wang JY, Lee J, Yan M, et al. Am J Pathol. 178(5):2168-2176. 2011.
10. Hu T, Ghazaryan S, Sy C, et al. Blood. 119(19):4532-4542. 2012.
11. Nakajima K, Maekawa Y, Kataoka K, et al. Nat Commun. 4:2112. 2013.
12. Ballas ZK, Buchta CM, Rosean TR, et al. PLoS One. 8(6):e65599. 2013.
13. Hogan T, Shuvaev A, Commenges D, et al. J Immunol. 190(8):3985-3993. 2013.
14. Reynolds C, Chong D, Raynsford E, et al. BMC Biol. 12:32. 2014.
15. Ying W, Tseng A, Chang RC, et al. Sci Rep. 6:20176. 2016.
16. Alrefai H, Muhammad K, Rudolf R, et al. Nat Commun. 7:11724. 2016.
17. Dutton EE, Camelo A, Sleeman M, et al. Wellcome Open Res. 2:117. 2017.
18. Freitas CMT, Hamblin GJ, Raymond CM, et al. PLoS One. 12(5):e0178799. 2017.
19. Early M, Schroeder WG, Unnithan R, et al. PeerJ. 5:e3555. 2017.
20. Hewitt KJ, Katsumura KR, Matson DR, et al. Dev Cell. 42(3):213-225.e4. 2017.
21. Kulkarni U, Herrmenau C, Win SJ, et al. PLoS One. 13(2):e0192304. 2018.
22. Lai D, Tang J, Chen L, et al. Cell Death Dis. 9(3):369. 2018.
23. Levy Y, Vagima Y, Tidhar A, et al. NPJ Vaccines. 3:52. 2018.
24. Moretti FA, Klapproth S, Ruppert R, et al. Elife. 7:e35816. 2018.
25. Niemeyer BF, Oko LM, Medina EM, et al. J Virol. 92(6):e01604-17. 2018.
26. Soukup AA, Zheng Y, Mehta C, et al. J Clin Invest. 129(3):1180-1192. 2019.
27. Ercoli G, Ramos-Sevillano E, Nakajima R, et al. Front Immunol. 11:611661. 2021.
28. Gilchrist AE, Harley BAC. Integr Biol (Camb). 12(7):175-187. 2020.
29. Pastrana-Otero I, Majumdar S, Gilchrist AE, et al. Analyst. 145(21):7030-7039. 2020.
30. Ngo MT, Barnhouse VR, Gilchrist AE, et al. Adv Funct Mater. 31(51):2101541. 2021.
31. Gilchrist AE, Serrano JF, Ngo MT, et al. Acta Biomater. 131:138-148. 2021.
32. Park JS, Lee D, Yang S, et al. J Transl Med. 20(1):85. 2022.
33. Xu L, Wei C, Chen Y, et al. Nat Commun. 13(1):6881. 2022.
34. Azam Z, Sapra L, Baghel K, et al. Cells. 12(2):216. 2023.
Flow Cytometry
IHC
Immunoprecipitation Protocol

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.